UBS AM
CABA icon

UBS AM’s Cabaletta Bio CABA Stock Holding History

UBS AM’s Portfolio CABA Stock Details CABA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-331,260
Closed -$1.56M – 2668
2024
Q3 		$1.56M Sell
331,260
-71,876
-18% -$416K ﹤0.01% 2173
2024
Q2 		$3.02M Buy
403,136
+390,215
+3,020% +$4.78M ﹤0.01% 1778
2024
Q1 		$220K Buy
12,921
+1,720
+15% +$36.9K ﹤0.01% 2446
2023
Q4 		$254K Buy
+11,201
New +$188K ﹤0.01% 2458

Other funds holding CABA

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
FAM
Fred Alger Management New York $22.8B AUM 64.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

UBS AM's CABA Position: Q4 2024 in Review

UBS AM sold out of Cabaletta Bio (CABA) in Q4 2024, closing a stake of 331,260 shares — an estimated $1.56M sold.

UBS AM first reported a position in CABA in Q4 2023 and held it in 4 quarters. The position peaked at $3.02M in Q2 2024. 108 funds tracked by Wall St. Rank hold CABA as of Q4 2024.

  • UBS AM reported no remaining Cabaletta Bio position as of Q4 2024 after selling out during the quarter.
  • UBS AM sold 331,260 Cabaletta Bio shares in Q4 2024, an estimated $1.56M.
  • UBS AM first reported a position in Cabaletta Bio in Q4 2023 and held it in 4 quarters.
  • UBS AM's Cabaletta Bio position peaked at $3.02M in Q2 2024.
  • 108 funds tracked by Wall St. Rank held Cabaletta Bio as of Q4 2024.

Based on UBS AM's 13F filing for Q4 2024, filed 14 Feb 2025.